Seizert Capital Partners LLC Purchases 1,283 Shares of Prestige Consumer Healthcare Inc. $PBH

Seizert Capital Partners LLC increased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 57,396 shares of the company’s stock after purchasing an additional 1,283 shares during the period. Seizert Capital Partners LLC’s holdings in Prestige Consumer Healthcare were worth $4,583,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC increased its stake in shares of Prestige Consumer Healthcare by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 27,307 shares of the company’s stock valued at $2,348,000 after purchasing an additional 4,343 shares during the last quarter. XTX Topco Ltd raised its stake in Prestige Consumer Healthcare by 354.0% during the first quarter. XTX Topco Ltd now owns 22,778 shares of the company’s stock worth $1,958,000 after acquiring an additional 17,761 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 19.5% in the first quarter. Voya Investment Management LLC now owns 41,717 shares of the company’s stock worth $3,586,000 after acquiring an additional 6,798 shares during the last quarter. Keystone Wealth Services LLC bought a new position in shares of Prestige Consumer Healthcare in the second quarter worth about $315,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Prestige Consumer Healthcare by 13.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,571 shares of the company’s stock valued at $765,000 after purchasing an additional 1,134 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PBH shares. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a research report on Wednesday, September 24th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Oppenheimer reduced their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $59.23 on Wednesday. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 13.90, a PEG ratio of 1.93 and a beta of 0.41. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a twelve month low of $58.50 and a twelve month high of $90.04. The stock has a fifty day simple moving average of $62.07 and a 200 day simple moving average of $72.07.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.